Teva Pharmaceutical Industries Limited (TEVA) Study Finds Gaps in Tardive Dyskinesia Care at Long-Term Facilities

A new study from Teva Pharmaceutical Industries Limited (NYSE:TEVA) has uncovered alarming gaps in the diagnosis and treatment of tardive dyskinesia (TD) among residents in long-term care (LTC) facilities. The research, presented today at Psych Congress Elevate, shows that over half of LTC residents with TD are not receiving the standard-of-care treatment, and 25% are left untreated altogether.

Teva Pharmaceutical Industries Limited (TEVA) Study Reveals Major Gaps in Tardive Dyskinesia Care in Long-Term Facilities

A manufacturer packaging eyecare products in a factory.

The study highlights that many LTC residents are misdiagnosed with the broader category of extrapyramidal syndrome (EPS), leading to inappropriate or insufficient treatment for TD. Only 1.1% of residents on antipsychotic drugs (APDs) had a specific TD diagnosis, while 5.6% were labeled with EPS. Most patients at risk for TD had comorbidities like dementia and heart failure.

Less than half of diagnosed TD patients received recommended VMAT2 inhibitor therapy; most were given non-FDA-approved drugs such as benztropine. Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s leadership emphasizes the urgent need for accurate diagnosis and timely intervention in LTC settings. Teva Pharmaceutical Industries Limited (NYSE:TEVA) pledges ongoing research to address these critical gaps and improve care for patients living with TD.

While we acknowledge the potential of TEVA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TEVA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.